Involvement of HMGB1 in Resistance to Tumor Vessel-Targeted, Monoclonal Antibody-Based Immunotherapy

HMGB1 induction of clusterin creates a chemoresistant niche in human prostate tumor cells

(2015) Junmin Zhou et al.   Scientific Reports

Cancer-associated fibroblasts induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells

(2015) Kamolporn Amornsupak et al.   BMC CANCER

Failure of anti tumor-derived endothelial cell immunotherapy depends on augmentation of tumor hypoxia

(2015) Annalisa Pezzolo et al.   Oncotarget

HIF2A and IGF2 Expression Correlates in Human Neuroblastoma Cells and Normal Immature Sympathetic Neuroblasts

(2015) Sofie Mohlin et al.   NEOPLASIA

HMGB1-dependent and -independent autophagy

(2014) Xiaofang Sun et al.   Autophagy

Inflammation, DAMPs, Tumor Development, and Progression: A Vicious Circle Orchestrated by Redox Signaling

(2013) Patrizia Castellani et al.   ANTIOXIDANTS & REDOX SIGNALING

HMGB1 in Cancer: Good, Bad, or Both?

(2013) R. Kang et al.   CLINICAL CANCER RESEARCH

Autophagy-mediated HMGB1 release antagonizes apoptosis of gastric cancer cells induced by vincristine via transcriptional regulation of Mcl-1

(2012) ZhenZhen Zhan et al.   Autophagy

High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases

(2012) Wei Yan et al.   HEPATOLOGY

HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4

(2012) Milena Schiraldi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release

(2012) Emilie Venereau et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1

(2012) Shigeki Chiba et al.   NATURE IMMUNOLOGY

Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1

(2012) J R van Beijnum et al.   ONCOGENE

In Vivo Evolution of Tumor-Derived Endothelial Cells

(2012) Terence F. McGuire et al.   PLoS One

HMGB1 Is a Therapeutic Target for Sterile Inflammation and Infection

(2011) Ulf Andersson et al.   Annual Review of Immunology

HMGB1 Promotes Drug Resistance in Osteosarcoma

(2011) J. Huang et al.   CANCER RESEARCH

Hypoxia-increased RAGE and P2X7R expression regulates tumor cell invasion through phosphorylation of Erk1/2 and Akt and nuclear translocation of NF-κB

(2011) Marco Tafani et al.   CARCINOGENESIS

Oct-4+/Tenascin C+ neuroblastoma cells serve as progenitors of tumor-derived endothelial cells

(2011) Annalisa Pezzolo et al.   CELL RESEARCH

High-Mobility Group Box Protein 1: A Novel Mediator of Inflammatory-Induced Renal Epithelial-Mesenchymal Transition

(2010) Julie Lynch et al.   AMERICAN JOURNAL OF NEPHROLOGY

HMGB1 and RAGE in Inflammation and Cancer

(2010) Gary P. Sims et al.   Annual Review of Immunology

Signalling pathways in vasculogenic mimicry

(2010) Yvette W.J. Paulis et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells

(2010) L Liu et al.   LEUKEMIA

Tumorigenesis: Twist1 links EMT to self-renewal

(2010) Alberto Martin et al.   NATURE CELL BIOLOGY

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

(2010) Alice L. Yu et al.   NEW ENGLAND JOURNAL OF MEDICINE

The basics of epithelial-mesenchymal transition

(2009) Raghu Kalluri et al.   JOURNAL OF CLINICAL INVESTIGATION

CD24 and Siglec-10 Selectively Repress Tissue Damage-Induced Immune Responses

(2009) G.-Y. Chen et al.   SCIENCE

RAGE signaling sustains inflammation and promotes tumor development

(2008) Christoffer Gebhardt et al.   JOURNAL OF EXPERIMENTAL MEDICINE